Black Diamond's Silevertinib Hits 86% CNS-ORR; FDA Backs Path to Registration
BDTX sits 26% above its 52-week low of $1.6.
Summary
Black Diamond reported updated Phase 2 silevertinib data (86% CNS-ORR in untreated brain metastases, 15.0-month mPFS) and said FDA feedback supports a Phase 3 program starting in Q2 2027 with a potential accelerated-approval path. Cash of $102.0 million funds operations into H2 2028.
Key Events · Product Development and Regulatory · BDTX
-
Updated Phase 2 Data Show Strong CNS Activity
As of an October 7, 2026 cutoff, 43 frontline EGFR-NCM NSCLC patients showed 60% ORR, 93% DCR and 15.0-month mPFS; the 16 patients with untreated brain metastases had 86% CNS-ORR (RANO-BM) and 12.2-month systemic mPFS.
-
FDA Feedback Supports Phase 3 Registration Path
The October 1, 2026 End-of-Phase 2 meeting supports a Phase 3 program in all 1L EGFR-NCM NSCLC patients, with potential accelerated approval on CNS-ORR by BICR and full approval on PFS by BICR.
-
Phase 3 Trial Planned for Q2 2027
The global trial would enroll 300 patients with untreated brain metastases randomized 1:1 to silevertinib 150 mg or osimertinib/afatinib, plus an 80-patient cohort without brain metastases and a 20-patient leptomeningeal cohort; preliminary data anticipated in 2028.
-
Cash Runway Into H2 2028
Cash, cash equivalents and investments were $102.0 million at September 30, 2026, down from $128.7 million at December 31, 2025; Q3 2026 net loss was $10.0 million and net cash used in operations was $8.3 million.
Analysis · BDTX · Life Sciences
The updated Phase 2 data and FDA feedback materially de-risk silevertinib's path to market. In 16 patients with untreated brain metastases, silevertinib produced an 86% CNS-ORR, and the 43-patient ITT group showed a 15.0-month mPFS — a figure the company says is double currently available EGFR TKIs. More important, the October 1 End-of-Phase 2 meeting gives a concrete regulatory route: a Phase 3 trial starting in Q2 2027 that could support accelerated approval on CNS-ORR and full approval on PFS. Against that, cash of $102.0 million funds operations into H2 2028, which covers the Phase 3 launch but leaves a funding gap before the 2028 data readout — a dilution risk that will hang over the stock.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 47.7% of the 1624 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDTX was trading at $2.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $106.9M. The 52-week trading range was $1.60 to $4.94. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.